DMAC Projected Dividend Yield
DiaMedica Therapeutics Inc ( NASDAQ : DMAC )DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. Co. is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. 20 YEAR PERFORMANCE RESULTS |
DMAC Dividend History Detail DMAC Dividend News DMAC Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |